• ABL Diagnostics was selected by the Évry Commercial Court to acquire TEXCELL’s assets and business operations.
• Project economic value estimated at about EUR 2.9 million, including an EUR 225,000 asset purchase price and EUR 1 million working-capital build.
• Deal includes EUR 30,000 inventory acquisition, about EUR 100,000 security deposits, lease-financing commitments of EUR 531,792.74.
• Operations will remain at Genopole in Évry-Courcouronnes; 29 employees transfer; headcount expected to rise by about five.
• TEXCELL generated about EUR 5.4 million revenue in fiscal 2024; acquisition expands ABL’s virology and biosafety services footprint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260723550701) on July 23, 2026, and is solely responsible for the information contained therein.